Bridged Diazepane Derivatives as Selective TASK-1/3 Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for obstructive and central sleep apnea, as well as snoring, lack effective and selective blockers for TASK-1 and TASK-3 channels, which are crucial for respiratory regulation and airway stability.
Innovation Solution
Development of novel imidazopyridinyl- or imidazopyrimidinyl-substituted bridged 1,4-diazepane derivatives that act as potent and selective blockers of TASK-1 and TASK-3 channels, potentially stabilizing airways and improving respiratory function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for sleep apnea are used, then respiratory disorders can be managed, but effective and selective blockers for TASK-1 and TASK-3 channels are lacking
Solution Approach 1:
The patent introduces specific substituent groups (imidazopyridinyl and imidazopyrimidinyl) at particular positions on the diazepane core structure to achieve selective binding to TASK-1 and TASK-3 channels. This localized modification of molecular properties enables the compound to interact specifically with target channels while maintaining overall structural stability.
Solution Approach 2:
The patent systematically varies parameters such as substituent types (R1-R6 groups), their positions, and stereochemical configurations to optimize both potency and selectivity. By changing these molecular parameters, the invention achieves compounds that selectively block TASK-1 and TASK-3 channels with high affinity, resolving the contradiction between general effectiveness and specific selectivity.
2Adaptability or versatility
If novel bridged diazepane derivatives are developed, then selective TASK-1 and TASK-3 channel blocking is achieved, but compound complexity increases
Solution Approach 1:
The bridged diazepane core structure serves multiple functions: it provides the fundamental pharmacophore for channel binding, enables selective interaction with TASK-1 and TASK-3 channels, and offers a scaffold for diverse substituent attachment. This multi-functional core reduces the need for entirely separate molecular frameworks for different selectivity requirements.
Solution Approach 2:
The molecule is divided into distinct functional segments: the bridged diazepane core and various substituent groups (R1-R6). This segmentation allows independent optimization of each component - the core provides structural stability and basic binding, while substituents fine-tune selectivity and potency, making the overall design more manageable despite complexity.
Data Source
AI summary
The present application relates to novel imidazopyridinyl- or imidazopyrimidinyl-substituted, bridged 1,4-diazepane derivatives of formula (I), to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of respiratory disorders including, sleep-related respiratory disorders such as obstructive sleep apnoeas and central sleep apnoeas and snoring. Formula (I) in which the ring Q represents a bridged 1,4-diazepane cycle.